Prudential PLC Sells 2,393 Shares of Amgen Inc. $AMGN

Prudential PLC lessened its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 5.3% in the 4th quarter, HoldingsChannel.com reports. The firm owned 42,965 shares of the medical research company’s stock after selling 2,393 shares during the period. Prudential PLC’s holdings in Amgen were worth $14,063,000 as of its most recent filing with the SEC.

Several other hedge funds have also bought and sold shares of AMGN. Norges Bank bought a new stake in Amgen during the fourth quarter valued at about $2,164,162,000. Capital World Investors boosted its stake in shares of Amgen by 11.5% in the third quarter. Capital World Investors now owns 18,795,474 shares of the medical research company’s stock worth $5,303,578,000 after acquiring an additional 1,935,876 shares during the period. Geode Capital Management LLC boosted its stake in shares of Amgen by 7.8% in the fourth quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock worth $4,665,822,000 after acquiring an additional 1,035,779 shares during the period. Vanguard Group Inc. boosted its stake in shares of Amgen by 1.8% in the fourth quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock worth $17,949,296,000 after acquiring an additional 961,975 shares during the period. Finally, National Bank of Canada FI boosted its stake in shares of Amgen by 237.7% in the third quarter. National Bank of Canada FI now owns 1,226,372 shares of the medical research company’s stock worth $346,076,000 after acquiring an additional 863,216 shares during the period. Institutional investors own 76.50% of the company’s stock.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen received European Commission marketing authorization for IMDYLLTRA® (tarlatamab) as a monotherapy for adults with extensive-stage small cell lung cancer, expanding a key oncology product into the European market and improving the drug’s commercial outlook. Article Title
• Positive Sentiment: Amgen also showed fresh momentum in autoimmune therapies, with new Phase 3 and real-world data on UPLIZNA and TAVNEOS presented at EULAR 2026, which supports the company’s growing presence in high-value specialty medicine niches. Article Title
• Positive Sentiment: One analyst note upgraded Amgen to a cautious Buy, citing improved fundamentals, a diversified pipeline, and growth drivers such as Imdelltra, Uplizna, Tepezza, and Repatha. Article Title

Insider Buying and Selling

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the transaction, the senior vice president directly owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.85% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. Daiwa Securities Group dropped their price objective on Amgen from $410.00 to $390.00 and set an “outperform” rating for the company in a research note on Wednesday, May 13th. The Goldman Sachs Group set a $389.00 price objective on Amgen in a research note on Friday. UBS Group upped their price objective on Amgen from $390.00 to $400.00 and gave the stock a “buy” rating in a research note on Monday, April 13th. Erste Group Bank reaffirmed a “hold” rating on shares of Amgen in a research note on Tuesday, May 5th. Finally, Truist Financial upped their price objective on Amgen from $325.00 to $327.00 and gave the stock a “hold” rating in a research note on Friday, May 1st. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, Amgen has an average rating of “Hold” and an average target price of $353.81.

Amgen Price Performance

Shares of Amgen stock opened at $349.58 on Friday. The stock has a 50 day moving average of $341.35 and a 200 day moving average of $345.47. Amgen Inc. has a 12 month low of $267.83 and a 12 month high of $391.29. The firm has a market cap of $188.67 billion, a PE ratio of 24.33, a PEG ratio of 3.47 and a beta of 0.42. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The company had revenue of $8.62 billion during the quarter, compared to analyst estimates of $8.58 billion. During the same period in the prior year, the company earned $4.90 earnings per share. The firm’s revenue was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, research analysts expect that Amgen Inc. will post 22.38 EPS for the current fiscal year.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.